Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Efavirenz liquid formulation in human immunodeficiency virus-infected children.

Starr SE, Fletcher CV, Spector SA, Brundage RC, Yong FH, Douglas SD, Flynn PM, Kline MW; PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group.

Pediatr Infect Dis J. 2002 Jul;21(7):659-63.

PMID:
12237599
2.

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.

Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM.

N Engl J Med. 1999 Dec 16;341(25):1874-81.

3.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

N Engl J Med. 2001 Aug 9;345(6):398-407.

4.

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, Paolucci S, Baldanti F, Tinelli C, Maserati R.

J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):453-60. Erratum in: J Acquir Immune Defic Syndr 2000 Mar 1;23(3):278.

PMID:
10961606
5.

Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.

Funk MB, Notheis G, Schuster T, Elanjkal Z, von Hentig N, Stürmer M, Linde R, Dunsch D, Königs C, Wintergerst U, Kreuz W.

Eur J Med Res. 2005 Dec 7;10(12):503-8.

PMID:
16356864
6.

Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

Kline MW, Brundage RC, Fletcher CV, Schwarzwald H, Calles NR, Buss NE, Snell P, DeLora P, Eason M, Jorga K, Craig C, Duff F.

Pediatr Infect Dis J. 2001 Jul;20(7):666-71.

PMID:
11465838
7.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
8.

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.

Fletcher CV, Brundage RC, Fenton T, Alvero CG, Powell C, Mofenson LM, Spector SA.

Clin Pharmacol Ther. 2008 Feb;83(2):300-6. Epub 2007 Jul 4.

9.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.

PMID:
10890257
10.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
11.

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.

Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H.

Clin Infect Dis. 2000 Feb;30(2):313-8.

PMID:
10671334
12.

Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.

Riddler SA, Havlir D, Squires KE, Kerr B, Lewis RH, Yeh K, Wynne LH, Zhong L, Peng Y, Deutsch P, Saah A.

Antimicrob Agents Chemother. 2002 Dec;46(12):3877-82.

13.

Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.

Barreiro P, Oller V, Soriano V, Nuñez M, Rodríguez-Rosado R, González-Lahoz J.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):391-2. No abstract available.

PMID:
11317086
14.

Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.

Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.

Pediatr Infect Dis J. 2006 Jun;25(6):538-43.

PMID:
16732153
15.

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

Sáez-Llorens X, Violari A, Deetz CO, Rode RA, Gomez P, Handelsman E, Pelton S, Ramilo O, Cahn P, Chadwick E, Allen U, Arpadi S, Castrejón MM, Heuser RS, Kempf DJ, Bertz RJ, Hsu AF, Bernstein B, Renz CL, Sun E.

Pediatr Infect Dis J. 2003 Mar;22(3):216-24.

PMID:
12634581
16.

Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children.

Engelhorn C, Hoffmann F, Notheis G, Funk M, Eberle J, Belohradsky BH, Wintergerst U.

Eur J Med Res. 2002 Jan 29;7(1):30-4.

PMID:
11827838
17.

Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.

de Truchis P, Force G, Welker Y, Mechali D, Pulik M, Chemlal K, Rouveix E, Devidas A, Praindhui D, Mamet JP; CNAF3008 Group.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):178-82.

PMID:
12394796
18.

Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, Starr SE, Spector SA.

J Infect Dis. 2002 May 15;185(10):1409-16. Epub 2002 Apr 30.

PMID:
11992275
19.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
20.

Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.

Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C.

J Antimicrob Chemother. 2000 Mar;45(3):343-7.

PMID:
10702554

Supplemental Content

Support Center